The Centers for Medicare & Medicaid Services has set the 2027 Part D national average monthly bid at $296.05, roughly a 24% jump from this year, and confirmed it is ending a temporary subsidy program that has kept stand-alone drug-plan premiums from rising as sharply since 2025. The base beneficiary premium for 2027 will be $41.33, and without the extra federal support that shaved $10 to $15 off premiums the past two years, CMS itself projects most stand-alone Part D members will see monthly premiums rise by up to $10 more than they otherwise would have.
Why CMS Is Ending the Part D Premium Stabilization Demonstration
CMS launched the Part D Premium Stabilization Demonstration in 2024 to smooth the transition to a redesigned Part D benefit under the Inflation Reduction Act, which capped out-of-pocket drug costs for enrollees but shifted more financial risk onto the insurers that sell stand-alone drug plans. According to the CMS fact sheet announcing the 2027 bid figures, the agency’s review of 2027 plan bids found that Part D sponsors now have sufficient experience managing the redesigned benefit, so CMS will discontinue the demonstration at the end of 2026 and return the program to what it calls traditional market conditions.
The demonstration worked by reducing the base beneficiary premium and capping how much any stand-alone plan’s premium could rise year over year. In 2025, its first year, the subsidy cut $15 from the base premium and limited a plan’s premium increase to no more than $35 a year, and it helped push stand-alone plan enrollment higher even as the redesigned benefit took effect nationwide for the first time.
For 2026, those parameters were scaled back to a $10 base-premium reduction and a $50 cap on the annual increase, a smaller cushion than the year before. According to a KFF analysis of the program, those subsidies reduced the average monthly stand-alone drug-plan premium by $26 in 2025 and by $16 in 2026, and stand-alone plan enrollment climbed from 22.8 million people in 2024 to 24.9 million in 2026 as the extra support kept premiums from spiking.
The subsidy’s cost was substantial: the demonstration totaled $9.8 billion in federal spending across its two years, a price tag that drew scrutiny from lawmakers who questioned the program’s rationale and asked the Government Accountability Office to examine it. Even with the subsidy in place, the average 2026 stand-alone drug-plan premium remained more than four times higher than the average premium enrollees pay for drug coverage bundled into a Medicare Advantage plan, $36 versus $8, because Medicare Advantage insurers can use other plan rebates to buy down their drug premiums in ways stand-alone plans cannot.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
What the 2027 Numbers Mean for a Stand-Alone Plan Member
For 2027, CMS calculates the national average monthly bid amount, the enrollment-weighted average of what Part D plans say it costs to offer basic coverage, at $296.05, a figure used to determine how much the government subsidizes each plan rather than what any individual pays out of pocket. The base beneficiary premium, the starting point insurers use to set an individual plan’s premium before adding coverage extras, will be $41.33, an increase that is capped under separate Inflation Reduction Act rules limiting the base premium’s year-over-year growth to no more than 6% through 2029.
Because the temporary demonstration no longer offsets that growth, CMS has said premiums will rise by less than $10 a month for most stand-alone Medicare drug-plan enrollees, with some enrollees potentially seeing flat or lower premiums depending on which plan they pick. That still represents a bigger jump than the past two years produced with the subsidy cushioning the increase, and the $10 figure is an average across the market rather than a per-plan ceiling.
The exact premium any one person pays will depend on the specific stand-alone plan and drug-tier structure they select during Medicare’s fall open enrollment period, since CMS does not finalize the complete 2027 Part D and Medicare Advantage plan landscape, including plan-by-plan premiums, until mid-to-late September. Enrollees whose current plan relied more heavily on the demonstration’s subsidy could see a premium increase well above the $10 average once insurers publish their actual 2027 rates.
The Underlying Cost Pressures Are Not Going Away
Even a full restoration of 2026-level subsidies would not have solved Part D’s deeper financial strain, since the demonstration’s temporary support never addressed the broader forces pushing plan costs higher: rising list prices for brand-name drugs and a surge in enrollee use of GLP-1 weight-loss and diabetes medications along with other expensive specialty drugs. Those cost pressures are expected to continue into 2027 and beyond regardless of whether CMS revives any comparable subsidy program in the future, meaning stand-alone drug-plan premiums are likely to keep climbing even after this particular support mechanism disappears.
For a retiree comparing plans this fall, the practical takeaway is that the sticker price on a stand-alone Part D plan is no longer being cushioned by the extra federal money that kept increases modest the past two years, and the roughly $10 gap CMS is flagging is only the market average. A close look at plan-specific pricing during open enrollment, rather than assuming this year’s plan will renew at a similar cost, is more consequential than it has been at any point since the redesigned Part D benefit first took effect.
This article was drafted with AI assistance and edited for accuracy.
More Financial Reading
